Trial Profile
A Randomized Comparison of Immediate Versus Deferred Androgen Deprivation Therapy Using Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Goserelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ELAAT
- 08 Jul 2016 Status changed from active, no longer recruiting to completed.
- 05 Jun 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015, according to ClinicalTrials.gov record.
- 05 Jun 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Jun 2015, according to ClinicalTrials.gov record.